FDA-Cleared, AI-Powered Sleep Diagnosis Using Pulse Oximeters

Accelerate the identification, diagnosis, and treatment of sleep disordered breathing with accurate, affordable, AI-driven analysis of photoplethysmogram (PPG) signals captured by pulse oximeters.

Expand Patient Access and Advance Home Sleep Testing

  • Up to 7 nights of testing at no additional cost

  • Affordable, comfortable, non-proprietary devices

  • Reusable or a single-patient disposable device

  • Custom reports for all devices in one platform

  • Accurate, unbiased, and clinically effective

Simple, Transparent Pricing (Twitter Post) (1)

Enhance Sleep Disorder Diagnosis and Patient Monitoring

  • FDA-cleared AI analysis powered by deep learning models

  • PPG-based studies validated against PSGs

  • Detects sleep disordered breathing events

  • Identifies sleep stages (REM, Deep Sleep, Light Sleep)

  • Uses signals clinicians are familiar with reading and interpreting

  • Displays an easy-to-read, editable sleep study for physician review

  • Exports final sleep report for patient diagnosis and treatment

  • Supports long-term patient monitoring

Access, review, and edit all AI-scored HSAT, PSG, and PPG-based sleep studies in Study Management

Multi-Night Testing Addresses Inter-Night Variability

Night-to-night variability in respiratory events during a single-night sleep study results in misclassification of more than 1 in 10 OSA patients, preventing them from receiving necessary therapy for their symptomatic sleep-disordered breathing.

 

EnsoSleep PPG effectively addresses inter-night variability by collecting and analyzing data from multiple nights of testing, helping healthcare providers account for fluctuations in sleep patterns and leading to more reliable diagnoses and personalized treatment for patients with sleep apnea.

Nathaniel F. Watson, MD, MSc, Chief Medical Officer, EnsoData; Past-President, AASM

“The high rate of missed diagnosis due to single-night testing gives the sleep medicine community the opportunity to reexamine current testing methods and explore the benefits of multi-night testing.

In terms of clinical effectiveness and the future of sleep medicine diagnostics, it may well be more productive to monitor one polysomnographic component for 20 nights rather than monitoring 20 components for one night.”

EnsoSleep PPG Clinical Performance

Three key metrics demonstrate the clinical impact of EnsoSleep PPG

Celeste is an HSAT solution that includes a mobile app (Android and iOS) to collect and transfer data from pulse oximeters, EnsoSleep PPG to analyze and score the data, and EnsoSleep PPG Study Management for viewing and editing reports.

EnsoSleep PPG Pricing

EnsoSleep PPG includes Study Management for viewing, editing, and reporting.  A monthly minimum and setup fee apply. Contact us to learn more.

$15/patient

Up to 7 consecutive nights 

Schedule a Demo

Explore EnsoSleep PPG for accessible, multi-night HSAT

Complete our form and tell us about your HSAT program and we’ll reach out to schedule a demo and answer your questions about EnsoSleep PPG.

We’d love to help you reach more patients and accelerate the identification, diagnosis, and treatment of sleep-disordered breathing with accurate, affordable, accessible multi-night home sleep testing using pulse ox devices.

To learn more, read our blog about the what, how, and why behind EnsoSleep PPG

Simplify and accelerate the sleep testing, diagnosis and treatment workflow for sleep clinicians and sleep labs with one cloud-based solution for sleep study viewing, editing, and reporting.

EnsoSleep FDA-cleared AI-assisted sleep scoring and analysis solution  automates the scoring of studies, and reduces the time RPSGTs spend scoring PSGs and HSATs. Consistent, reliable results provide clinicians with more time to expand patient care, improve outcomes and treat more patients.

EnsoSleep produces an accurate Total Sleep Time (TST) for HSAT devices that do not calculate a measurement of sleep time. Including TST results in improved diagnostic accuracy for clinicians and patients and potential increased reimbursement.